Cencora (COR): Officer exercised options on 1,974 units
Pawan Verma, Officer at Cencora, reported an option exercise of 1,974 units.
- 1,974
- Derivative units
- Traded
- Nov 20, 2025
- Filed
- Nov 25, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 18, 2025InsiderCEO sold ~$1.48M of COR shares in the open market
- Oct 1, 2025InsiderOfficer sold ~$591K of COR shares in the open market
- Oct 9, 2025FDARecall: Sucralfate Tablets, USP 1 gram, 100 Tablets, (10x10), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 60687-695-01 - Carton NDC […
- Oct 16, 2025FDARecall: Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons, Rx only, Distributed by American Health Packaging, Columbus, Ohio 43217, carton NDC 606…
- Oct 16, 2025FDARecall: Prazosin Hydrochloride, Capsules, USP, 2 mg, 100 capsules (10x10) cartons, Rx only, Distributed by American Health Packaging, Columbus, Ohio 43217, Carton NDC…
- Oct 16, 2025FDARecall: Prazosin Hydrochloride, Capsules, USP, 1 mg, 100 capsules (10x10) cartons, Rx only, Distributed by American Health Packaging, Columbus, Ohio 43217, Carton NDC…
- Oct 20, 2025InsiderCEO sold ~$1.67M of COR shares in the open market
- Nov 5, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- Nov 18, 2025InsiderCEO sold ~$1.87M of COR shares in the open market
What came next
- Dec 17, 2025InsiderOfficer sold ~$1.38M of COR shares in the open market
- Dec 18, 2025InsiderCEO sold ~$1.75M of COR shares in the open market
- Dec 19, 2025Insider · 2 peopleInsiders: 2 sales (~$1.7M)
- Jan 12, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
- Jan 14, 2026FDARecall: Oxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) blister cards per carton, Rx Only, The drug product contained in this package is from NDC…
- Jan 16, 2026Federal contract · $7.7M obligatedDepartment of Defense awarded Cencora: $7.74M obligated to date
- Jan 20, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On January 20, 2026, the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Ellen G. Cooper to serve on the Board (the “Appointment”), effective immediately.”
- Jan 20, 2026Insider · 13 days before resultsCEO sold ~$1.81M of COR shares in the open market
- Feb 2, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- Feb 13, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
- Feb 18, 2026InsiderCEO sold ~$479K of COR shares in the open market
- Feb 20, 2026InsiderCEO sold ~$1.35M of COR shares in the open market
- Mar 16, 2026FDARecall: Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Distributed…
- Mar 17, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 17, 2026, Cencora, Inc. (the “Company”) announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026.”
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Cencora
For Cencora, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its COR page.
How this filing works
Explore the data
Common questions
Which Cencora (COR) insider traded, and how much?
Pawan Verma, Officer at Cencora, reported an option exercise of 1,974 units. Not an open-market trade.
When did it happen, and when was it made public?
Traded: Nov 20, 2025. Filed: Nov 25, 2025. That is 5 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Cencora recently?
For Cencora, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the COR page.
Does this mean COR stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Cencora
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 3, 2026
- SEC Form 4Oct 5, 2026
- SEC Form 4Sep 17, 2026
- SEC Form 144Sep 16, 2026
- SEC Form 144Sep 11, 2026
Everything OQRO holds on this company is on its COR page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
